| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $503,349,198 ) (Continued on the next page) |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | K08EY038342 | Development and regeneration of retinal ganglion cells in the vertebrate retina | 000 | 1 | NIH | 4/16/2026 | $255,340 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | RF1MH139950 | Neuromodulatory system abnormalities in late life depression: Associations with mood, cognition, and motor frailty | 000 | 2 | NIH | 6/12/2026 | $3,131,019 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | F31AI197619 | Impact of biophysical tradeoffs on antibody affinity maturation against SARS-CoV-2 | 000 | 1 | NIH | 4/6/2026 | $49,617 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | F31AI197619 | Impact of biophysical tradeoffs on antibody affinity maturation against SARS-CoV-2 | 001 | 1 | NIH | 4/6/2026 | $0 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R13CA310705 | RISE UP for Breast Cancer 2026 | 000 | 1 | NIH | 2/9/2026 | $12,500 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R01CA311659 | Covalent Inhibitors of Ras Q61 Mutations in Cancer | 000 | 1 | NIH | 5/19/2026 | $675,009 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R01AI197356 | Interplay of heterosexual male-female partner microbiomes, Chlamydia trachomatis and transmission | 000 | 1 | NIH | 4/6/2026 | $816,421 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R01NS148534 | Striatal Synaptic Plasticity in the Cognitive Aspects of Parkinsons Disease | 000 | 1 | NIH | 5/19/2026 | $595,208 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R01AG075742 | Vitamin D and beta-amyloid signaling in hyperparathyroidism | 000 | 2 | NIH | 4/6/2026 | $756,962 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | T32MH139734 | Training the Next Generation of Clinical Researchers in Stress Mechanisms and Mental Health | 000 | 1 | NIH | 6/22/2026 | $184,649 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | K01DA063772 | Spatiotemporal dynamics of G protein signaling by opioid receptors | 000 | 1 | NIH | 6/23/2026 | $200,880 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R35GM163663 | Next Generation Visualization and Analysis Software for Multiscale Modeling | 000 | 1 | NIH | 4/10/2026 | $562,484 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | UG3NS146003 | Multisite closed loop DBS for Chronic Pain | 000 | 1 | NIH | 4/21/2026 | $387,647 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | K99GM163003 | De novo Design of Proteins for Catalysis and Fluorescence Imaging | 000 | 1 | NIH | 3/20/2026 | $124,767 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R21HL177738 | Calculating In-patient Ventricular Tachycardia Burden and Assessing its Impact on Outcomes | 000 | 1 | NIH | 7/9/2026 | $246,000 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R01DK147593 | Leveraging a Novel Neural Circuit for Urinary and Fecal Incontinence | 000 | 1 | NIH | 4/13/2026 | $512,595 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | UG1EY038172 | Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial | 000 | 1 | NIH | 4/27/2026 | $1,655,047 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | UG1EY038172 | Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial | 002 | 1 | NIH | 5/15/2026 | $0 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | UG1EY038172 | Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial | 003 | 1 | NIH | 5/19/2026 | $0 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | UG1EY038172 | Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial | 004 | 1 | NIH | 5/28/2026 | $58,047 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | U01NS146166 | Prenatal AAV9 gene replacement therapy for patients with severe infantile GM1 gangliosidosis | 000 | 1 | NIH | 3/23/2026 | $649,600 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01AI196019 | Immunogenetic determinants of response to drug-susceptible tuberculosis treatment | 000 | 1 | NIH | 2/9/2026 | $842,888 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | DP2DA066200 | Psilocybin Therapy for Methamphetamine Use Disorder and HIV | 000 | 1 | NIH | 7/10/2026 | $2,460,000 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | UG1EY038172 | Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial | 001 | 1 | NIH | 5/7/2026 | $7,400 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | UH3NS140730 | Simplified, Scalable 24-hour adaptive deep brain stimulation for Parkinson’s disease | 000 | 2 | NIH | 5/19/2026 | $2,095,406 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R03AI190673 | Development of a Humanized IL33 Mouse | 000 | 1 | NIH | 4/6/2026 | $174,824 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | F32MH140488 | Mechanisms of Dopamine D3 Receptor Mediated Antipsychotic Action in the Hippocampus | 001 | 1 | NIH | 4/3/2026 | $0 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | F32MH140488 | Mechanisms of Dopamine D3 Receptor Mediated Antipsychotic Action in the Hippocampus | 000 | 1 | NIH | 4/3/2026 | $76,780 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R13HD122340 | Advancing Precision Pharmacology for Maternal and Child Health | 000 | 1 | NIH | 4/24/2026 | $20,000 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01DK147971 | ASB4 in feeding regulation | 000 | 1 | NIH | 5/8/2026 | $607,612 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | K23MH138756 | Understanding and Altering Prenatal Immune Function and Parenting to Improve Child Mental Health: Investigating Intergenerational Stress Transmission Mechanisms | 000 | 1 | NIH | 3/19/2026 | $200,376 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01NS128217 | Gene therapy for disorders of the extracellular matrix | 000 | 2 | NIH | 4/24/2026 | $821,991 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R33AG087921 | Exploring the differential spreading of distinct pathological conformers of AD/LBD-related proteins by combining mathematical modeling and functional study | 000 | 3 | NIH | 7/3/2026 | $793,233 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | K23AG090757 | Deciphering the molecular landscape of frontotemporal lobar degeneration: A network-based proteomic approach | 000 | 2 | NIH | 5/8/2026 | $200,182 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01MH139197 | Molecular and functional dissection of prefrontal-hippocampal long-range inhibition | 000 | 1 | NIH | 3/10/2026 | $800,384 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01AG094900 | Policing, Housing, and Health Outcomes in Older Homeless Adults | 000 | 2 | NIH | 4/20/2026 | $676,516 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | K01AG094343 | Strengthening Clinical Support for Providers Working with Women Living with HIV to Manage Menopause | 001 | 2 | NIH | 5/19/2026 | $131,598 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01HL138626 | The Role of Early-Life Viral Respiratory Illness in Development of Childhood Asthma Endotypes: the PRIMERO II study | 000 | 6 | NIH | 5/8/2026 | $1,319,983 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | K08CA312446 | Targeting TOX-Imposed Epigenetic and Transcriptional Circuits to Restore T Cell Function in Cancer | 000 | 1 | NIH | 7/3/2026 | $237,546 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01AI197222 | AMR Monitoring to Improve Child’s Health and Mortality | 000 | 1 | NIH | 6/29/2026 | $597,421 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01CA311995 | Defining and overriding mechanisms of in vitro and clinical resistance to the first highly active allosteric kinase inhibitor | 000 | 1 | NIH | 5/11/2026 | $700,338 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01AI189532 | Biophysical constraints on antibody affinity maturation to SARS-CoV-2 | 000 | 1 | NIH | 2/19/2026 | $815,762 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R01AI200744 | Modeling dynamic CD8+ T cell-virus interactions in post-treatment control of HIV | 000 | 1 | NIH | 5/11/2026 | $874,531 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R03MH139969 | Exposure to violence and food and mental health security in the occupied Palestinian territories | 000 | 1 | NIH | 5/6/2026 | $164,000 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | R56AG046400 | Linking metabolism, neural function, and aging | 000 | 11 | NIH | 12/29/2025 | $537,590 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103-4249 | SAN FRANCISCO | USA | R56AG046400 | Linking metabolism, neural function, and aging | 001 | 11 | NIH | 5/29/2026 | $0 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | K99AG097973 | Mapping cerebellar influence in FTD: unraveling the role of the cerebellum in social cognition and clinical trajectory | 000 | 1 | NIH | 2/27/2026 | $119,785 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | F31AI200462 | Elucidating the biophysical basis of repeatability in the evolution of drug resistance | 000 | 1 | NIH | 5/11/2026 | $44,000 |
| | 2026 | 2026 | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE | 1855 FOLSOM ST STE 425 | SAN FRANCISCO | CA | 94103 | SAN FRANCISCO | USA | F31AI200462 | Elucidating the biophysical basis of repeatability in the evolution of drug resistance | 001 | 1 | NIH | 5/11/2026 | $0 |
|
